Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Account Payables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Change in Account Payables for 3 consecutive years, with -$150000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 82.93% to -$150000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$760000.0, a 246.44% decrease, with the full-year FY2025 number at -$760000.0, down 246.44% from a year prior.
  • Change in Account Payables was -$150000.0 for Q4 2025 at Artiva Biotherapeutics, up from -$442000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $851000.0 in Q1 2024 to a low of -$1.9 million in Q4 2023.
  • A 3-year average of -$240333.3 and a median of -$150000.0 in 2025 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: skyrocketed 95.73% in 2024, then plummeted 162.78% in 2025.
  • Artiva Biotherapeutics' Change in Account Payables stood at -$1.9 million in 2023, then surged by 95.73% to -$82000.0 in 2024, then tumbled by 82.93% to -$150000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Change in Account Payables are -$150000.0 (Q4 2025), -$442000.0 (Q3 2025), and -$209000.0 (Q2 2025).